Skip to main content
Erschienen in: Wiener klinische Wochenschrift 19-20/2015

01.10.2015 | original article

Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD

verfasst von: Hakan Tanrıverdi, MD, Tacettin Örnek, MD, Fatma Erboy, MD, Bülent Altınsoy, MD, Fırat Uygur, MD, Prof. Dr. Figen Atalay, MD, Prof. Dr. Müge Meltem Tor, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2015

Einloggen, um Zugang zu erhalten

Summary

Background

Viral or bacterial upper respiratory infections are the most common cause of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Based on available data, no reliable parameter has been presented to distinguish between bacterial and nonbacterial exacerbations. Therefore, we compared the diagnostic value of procalcitonin (PCT) level, which is a newer marker for predicting bacterial infections in patients with AECOPD, to routine parameters such as C-reactive protein (CRP) levels and the neutrophil/lymphocyte (N/L) ratio.

Methods

This study included all consecutive patients who were admitted for a diagnosis of AECOPD between January 1 and March 31, 2014. PCT, CRP, and the N/L ratio were assessed in addition to cultures from tracheal aspirates or sputum on the first day of admission. Patients with a pneumonic infiltration on chest radiographs, or an extrapulmonary infection focus, or whose blood samples were not obtained for PCT and/or CRP at the same time as sputum culture were excluded from the study.

Results

A total of 77 patients were included with a mean age of 71.7 ± 9.5 years. Bacteria were isolated in 37.4 % of the patients. Mean PCT levels were significantly higher in patients with positive sputum cultures than in patients with negative sputum cultures. The cut-off values for PCT, CRP, and the N/L ratio for predicting a bacterial infection were 0.40 ng/mL, 91.50 mg/L, and 11.5, respectively; sensitivity was 61, 54, and 61 % respectively; specificity was 67, 52, and 58 %, respectively; and the area under the curve (AUC) values were 0.64, 0.52, and 0.58, respectively. The AUC value of PCT was significantly better for predicting bacterial infection compared with the CRP level or the N/L ratio (p = 0.042).

Conclusion

PCT was better than CRP and the N/L ratio for predicting a bacterial infection in hospitalized patients with AECOPD. However, we find PCT not so reliable in predicting bacterial infection in AECOPD due to sensitivity and specificity of less than 80 % and a low AUC value.
Literatur
2.
Zurück zum Zitat Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998;92:664–7.CrossRefPubMed Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998;92:664–7.CrossRefPubMed
3.
Zurück zum Zitat Torres A. COPD guidelines in relation to infections: a critical analysis. Breathe. 2009;5(4):317–32. doi:10.1183/18106838.0504.317.CrossRef Torres A. COPD guidelines in relation to infections: a critical analysis. Breathe. 2009;5(4):317–32. doi:10.1183/18106838.0504.317.CrossRef
4.
Zurück zum Zitat Lacoma A, Prat C, Andreo F, et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J COPD. 2011;6:157–69. Lacoma A, Prat C, Andreo F, et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J COPD. 2011;6:157–69.
5.
Zurück zum Zitat Daniels JMA, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138(5):1108–15.CrossRefPubMed Daniels JMA, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010;138(5):1108–15.CrossRefPubMed
6.
Zurück zum Zitat Nuutilia J, Lilius EM. Distinction between bacterial and viral infections. Curr Opin Pulm Med. 2007;20:304–10. Nuutilia J, Lilius EM. Distinction between bacterial and viral infections. Curr Opin Pulm Med. 2007;20:304–10.
7.
Zurück zum Zitat Wedzicha JA. Exacerbations: etiology and pathophysiologic mechanisms. Chest. 2002;121:136–41.CrossRef Wedzicha JA. Exacerbations: etiology and pathophysiologic mechanisms. Chest. 2002;121:136–41.CrossRef
8.
Zurück zum Zitat Polzin A, Pletz M, Erbes R. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 2003;21:939–43. doi:10.1183/09031936.03.00055103CrossRefPubMed Polzin A, Pletz M, Erbes R. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 2003;21:939–43. doi:10.1183/09031936.03.00055103CrossRefPubMed
9.
Zurück zum Zitat Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med. 2009;15:120–5.CrossRefPubMed Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med. 2009;15:120–5.CrossRefPubMed
10.
Zurück zum Zitat Günay E, Sarınç UlaşlıS, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation. 2014;37:2. doi:10.1007/s10753-013-9749-1.CrossRef Günay E, Sarınç UlaşlıS, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation. 2014;37:2. doi:10.1007/s10753-013-9749-1.CrossRef
11.
Zurück zum Zitat Mohamed KH, Abderabo MM, Ramadan ES, et al. Procalcitonin as a diagnostic marker in acute exacerbation of COPD. Egypt J Chest Dis Tuberculosis. 2012;61:301–5.CrossRef Mohamed KH, Abderabo MM, Ramadan ES, et al. Procalcitonin as a diagnostic marker in acute exacerbation of COPD. Egypt J Chest Dis Tuberculosis. 2012;61:301–5.CrossRef
12.
Zurück zum Zitat Delèvaux I, André M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis. 2003;62:337–40.PubMedCentralCrossRefPubMed Delèvaux I, André M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis. 2003;62:337–40.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and c-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17.CrossRefPubMed Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and c-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17.CrossRefPubMed
14.
Zurück zum Zitat Daubin C, Parienti JJ, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis. 2008;8:145. doi:10.1186/1471-2334-8-145.PubMedCentralCrossRefPubMed Daubin C, Parienti JJ, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis. 2008;8:145. doi:10.1186/1471-2334-8-145.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Ko FWS, Ng TKC, Li TST, et al. Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong. Respir Med. 2005;99:454–60.CrossRefPubMed Ko FWS, Ng TKC, Li TST, et al. Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong. Respir Med. 2005;99:454–60.CrossRefPubMed
16.
Zurück zum Zitat Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410–8.PubMedCentralCrossRefPubMed Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410–8.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Kherad O, Bridevaux PO, Kaiser L, et al. Is acute exacerbation of COPD (AECOPD) related to viral infection associated with subsequent mortality or exacerbation rate? Open Respir Medi J. 2014;8:18–21.CrossRef Kherad O, Bridevaux PO, Kaiser L, et al. Is acute exacerbation of COPD (AECOPD) related to viral infection associated with subsequent mortality or exacerbation rate? Open Respir Medi J. 2014;8:18–21.CrossRef
18.
Zurück zum Zitat Domenech A, Puig C, Martí S, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect. 2013;67:516–23.CrossRefPubMed Domenech A, Puig C, Martí S, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect. 2013;67:516–23.CrossRefPubMed
19.
Zurück zum Zitat Lieberman D, Lieberman D, Ben-Yaakov M, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001;40(3):95–102.CrossRefPubMed Lieberman D, Lieberman D, Ben-Yaakov M, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001;40(3):95–102.CrossRefPubMed
20.
Zurück zum Zitat Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci. 2013;345(3):190–4.CrossRefPubMed Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci. 2013;345(3):190–4.CrossRefPubMed
21.
Zurück zum Zitat Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS,. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care. 2006;10(2):R53.PubMedCentralCrossRefPubMed Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS,. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care. 2006;10(2):R53.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat De Jager CPC, van Wijk PTL, Mathoera RB, et al. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care. 2010;14:R192.PubMedCentralCrossRefPubMed De Jager CPC, van Wijk PTL, Mathoera RB, et al. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care. 2010;14:R192.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Bartlett JG, Senthi S. Management of infection in exacerbations of chronic obstructive pulmonary disease. In Sexton JD, editor. UpToDate. Waltham. http://www.uptodate.com. Accessed 6 June 2014. Bartlett JG, Senthi S. Management of infection in exacerbations of chronic obstructive pulmonary disease. In Sexton JD, editor. UpToDate. Waltham. http://​www.​uptodate.​com. Accessed 6 June 2014.
24.
Zurück zum Zitat Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27:358–63.CrossRefPubMed Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27:358–63.CrossRefPubMed
Metadaten
Titel
Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD
verfasst von
Hakan Tanrıverdi, MD
Tacettin Örnek, MD
Fatma Erboy, MD
Bülent Altınsoy, MD
Fırat Uygur, MD
Prof. Dr. Figen Atalay, MD
Prof. Dr. Müge Meltem Tor, MD
Publikationsdatum
01.10.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0690-6

Weitere Artikel der Ausgabe 19-20/2015

Wiener klinische Wochenschrift 19-20/2015 Zur Ausgabe